Slideshow
5 Qs on Vaccines and Guillain-Barre Syndrome
Author(s):
What is the most common risk factor for Guillain-Barré Syndrome? Plus 4 other quick questions to test your knowledge.
Test your knowledge on vaccines and Guillain-Barré Syndrome with the 5 questions below.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Videos
Key Considerations in Treatment of Spinal Muscular Atrophy / Considerações essenciais para o tratamento da atrofia muscular espinhal
Rare Diseases Awareness and Educational Needs / Conscientização sobre doenças raras e necessidades educacionais
Spinal Muscular Atrophy Resources for Clinicians and Families / Recursos sobre atrofia muscular espinhal para profissionais de saúde e familiares
Access to Clinical Trials for Spinal Muscular Atrophy in Brazil / Acesso a testes clínicos para atrofia muscular espinhal no Brasil
Challenges in Spinal Muscular Atrophy Monitoring, Management and Access to Care in Brazil / Desafios no monitoramento da atrofia muscular espinhal, manejo e acesso a atendimento de saúde no Brasil
Management Based on Type of Spinal Muscular Atrophy, Patient Needs, and Age / Manejo baseado no tipo de atrofia muscular espinhal, necessidades e idade do paciente
Monitoring and Management of Family Expectations During Spinal Muscular Atrophy Treatment / Monitoramento e manejo de expectativas das famílias durante o tratamento da AME
Role of Primary Care Providers and Pediatricians in Monitoring and Management of Spinal Muscular Atrophy / Papel de médicos da atenção primária e pediatras no monitoramento da atrofia muscular espinhal
Short-Term and Long-Term Care for Patients on Spinal Muscular Atrophy Treatment / Cuidados de curto e longo prazo para pacientes em tratamento para atrofia muscular espinhal
Ideal Patient Profiles for Spinal Muscular Atrophy Therapies / Perfis ideais de pacientes para tratamento da atrofia muscular espinhal
Related Content
